跳至主要内容
临床试验/ACTRN12612000503820
ACTRN12612000503820已完成未知

In preterm infants born at <29 weeks gestation is an emulsion containing a higher amount of docosahexaenoic acid (DHA) more effective than an emulsion with no additional DHA in reducing the incidence of bronchopulmonary dysplasia at 36 weeks post menstrual age?

South Australian Health and Medical Research Institute0 个研究点目标入组 1,273 人开始时间: 2012年5月9日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
1,273

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
o limit 至 o limit(—)
性别
All

入选标准

  • Born at less than 29 weeks gestational age
  • Within 3 days of commencing enteral feeds
  • Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the infant’s behalf

排除标准

  • Infants who have a major congenital or chromosomal abnormality will be excluded from the study
  • Women providing breast milk who are taking supplements providing >250 mg DHA per day and do not wish to stop taking supplements.
  • Infants participating in another fatty acid study.
  • Infants receiving intravenous lipid emulsions containing fish oil given as early lipid parenteral nutrition support.

研究者

相似试验